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Abstract Despite substantial progress in the management
and outcome of acute promyelocytic leukemia (APL) during
the last decades, older age remains a prominent negative
prognostic factor. The improvement of long-term stabiliza-
tion and cure of older APL patients is therefore a particular
challenge. Data of unselected population-based studies sug-
gest a high rate of exclusion from clinical trials in older age.
The comparison of registry and study data indicates that
study patients represent a positive selection. Older APL
patients seem as sensitive to therapy as younger patients.
With conventional therapy, based on all-trans retinoic acid
(ATRA) and chemotherapy, over 50 % of older APL patients
can probably be cured. Special problems of advanced age
are the high rate of early death before or during induction
therapy and the high frequency of death in remission with
negative influence on the outcome. Both may be related in
part to a higher vulnerability against the common treatment
with ATRA and chemotherapy. Alternative less toxic ap-
proaches including arsenic trioxide (ATO) with or without
ATRA and combinations with gemtuzumab ozogamicin or
with reduced chemotherapy can induce long-lasting remis-
sion in all stages of APL. Considering the high curative
potential and the excellent tolerance of ATO in newly diag-
nosed and relapsed APL, older patients are probably a
particular target group for a chemotherapy-free approach
with ATO.
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Introduction
Acute promyelocytic leukemia (APL) accounts for approx-
imately 5–10 % of cases of acute myeloid leukemia (AML).
It can be differentiated from all other forms of leukemia by
its characteristic morphology (AML FAB M3/M3v) and by
the diagnostic chromosomal translocation t(15;17) with cor-
responding PML-RARA and RARA-PML fusion genes
[1–6]. Accompanying coagulation disorders promote the
appearance of life-threatening hemorrhages, which are the
most frequent cause of death in the early phase of the
disease [7, 8]. Approximately 20 to 30 % of patients present
with high white blood cell (WBC) counts associated with an
inferior prognosis [9–11]. Other unfavorable prognostic fac-
tors are the expression of the CD56 antigen and the detec-
tion of FLT3 mutations [12–14]. Even in the presence of
negative factors, the prognosis of APL still remains favor-
able in comparison to other AML subtypes if the patients
receive the common treatment with all-trans retinoic acid
(ATRA) and chemotherapy. The median age of patients
included in larger trials is almost 40 to 45 years [15–23]
(Table 1). With current treatment strategies, approximately
80 % of patients with APL included in trials can be cured
[24, 25]. Older age, however, remains a striking negative
prognostic factor despite improvement of prognosis over the
last decades. The great majority of clinical reports on APL
have focused on the progress of the younger age groups. It is
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the aim of the present review to give an overview on
incidence, clinical characteristics, special problems, and
treatment results of the elderly APL patients.
Incidence of APL in elderly patients and inclusion
in clinical trials
It was primarily assumed that APL is less frequent in older
patients. Based on data of the British Leukemia registries
published in the year 2000, the incidence of APL was
reported to be very low in children below the age of 10 years.
Above this age limit, the incidence appeared approximately
constant with increasing age [26]. Recently published re-
sults of other registries even show a significant increase of
the incidence of APL in older age [27–30]. Details are
shown in Table 2.
Compared to these unselected population-based studies,
the rate of older patients included in clinical trials was
mostly lower and ranged from 6 to 26 % in patients over
60 years and from 3 to 9 % at age over 70 years (Table 1)
[15–23]. The percentage of elderly study patients assigned
Table 1 Overview of the rate of older APL patients included in multicenter trials with ATRA and chemotherapy




≥60 years (%) ≥70 years (%) Total patients with
high risk (%)
Kanamaru (1995) [15] 109 43 (16–74) – 7 (>69 years) –
Burnett (1999) [16] 239 n.r. (<14–60+) 12 3 27
Tallman (2002) [18] 300 38 (1–81) 10 (>65 years) – –
Ades (2005) [19, 33] 533 46 (32–70) 24 6 –
Sanz (2010) [20] 963 41 (18–70+) 17 6 27
Burnett (2012) [21] 285 42 (16–69) 6 0 21
Lengfelder (2013) [22, 23] 260 51 (16–87) 26 9 28
n.r. not reported
Table 2 Results of population-based studies indicating higher incidence of APL and higher early death rate with increasing age
Author (year) [reference] Age groups (years) No. of pts Incidence
per 100,000
Early death p value Outcome p value
Park (2011) [28] Probability
of ED (%)
Survival rate (%)
1 year 3 years
<35 433 0.13 12.3 <0.001 81.2 76.3 <0.001
35–54 463 0.26 16.0 75.6 72.0
≥54 502 0.42 24.2 53.2 46.4
Total 1,400




1 year 5 years
<20 149 0.06 n.r. 0.79 0.52
20–39 372 0.19 n.r. 0.71 0.57
40–59 427 0.22 n.r. 0.67 0.57
≥60 449 0.36 n.r. 0.38 0.24
Total 1,397
Lehmann (2011) [27] Rate of ED (%) Survival rate (%)a
1 year 5 years
<40 28 19 82 82
40–59 37 16 83 74
≥60 40 50 37 24
Total 105
n.r. not reported, pts patients, ED early death
a Approximate values extracted from survival curves
1182 Ann Hematol (2013) 92:1181–1188
to the high-risk group, according to the Sanz score, varied
considerably and was mostly lower compared to the total
study populations covering all age groups (Tables 1 and 3)
[23, 31–35]. These observations suggest that a considerable
rate of elderly patients is not included in clinical trials, in
particular those with high-risk disease (high risk according
to Sanz score: WBC count >10,000/μl, intermediate risk:
WBC count ≤10,000/μl and platelet count ≤40,000/μl, low
risk: WBC count ≤10,000/μl and platelet count >40,000/μl)
[9].
Rate and reasons of early death in elderly APL patients
Despite improvement of prognosis in APL by the introduction
of ATRA, the early death (ED) rate remained relatively high.
According to the results of the Surveillance, Epidemiology,
and End Results (SEER) database from the USA, treatment
advances did not improve the 30-day mortality significantly,
being approximately 20 % from 1977 to 2007 [36]. Other
results of registries and of clinical trials showed that increasing
age, worse performance status, and high WBC count have a
negative impact on the ED rate [10, 23, 27].
In clinical trials, the ED rate of elderly APL patients was
high and ranged between 10 and 18 % (Table 4) [23, 31–35].
The ED rate observed in population-based registries including
unselected patients was even higher. An epidemiologic study
from the USA reported an ED rate of 24 % in 502 patients
aged over 54 years [28]. In the Swedish Adult Acute Leuke-
mia registry, the ED rate of all 105 registered APL patients
(age, 18 to 86 years) was 29 %, and for patients over 60 years,
it was 50 % (Table 2) [27]. The German AML Cooperative
Group (AMLCG) reported on 91 (30 %) registered patients
aged 60 to 83 years among 305 patients with newly diagnosed
APL. Of these elderly patients, 25 % were not eligible for
inclusion in the studies. The 30-day mortality rate of the non-
eligible patients was 48 % [23].
Detailed analyses of the causes of death indicated that
ED in younger APL patients is more frequently due to
hemorrhages, whereas in older patients, the causes of ED
are more variable including a high rate of death from
sepsis or multiorgan failure [22, 23, 27]. The registry
reports further demonstrate that age over 60 years was
associated with a significantly shorter overall survival
mainly influenced by the high rate of ED (Table 2)
[27–30].
Results of clinical studies with ATRA and chemotherapy
Before the introduction of ATRA, 25 to 50 % of patients
with APL were probably cured by frontline therapy with
anthracyclines and cytosine arabinoside (ara-C) [37]. Inves-
tigational studies with chemotherapy before the advent of
ATRA showed that increasing cumulative anthracycline
doses and the application of maintenance chemotherapy
reduced the relapse rate significantly [38, 39]. Older age,
microgranular variant, high leukocyte count, and severe
coagulopathy were adverse prognostic factors. By combina-
tion of anthracycline-based chemotherapy with ATRA, the
rate of early death and the frequency of relapses were
reduced resulting in a significant improvement of long-
term survival and probable cure [37]. It was the aim of
subsequent studies to optimize the combination of ATRA
and chemotherapy regimens, which were mostly adopted
from AML treatment. These studies mainly focused on
younger APL patients who had no contraindications against
intensive therapy and included only smaller proportions of
older patients (Table 1).
Most of the study data of the elderly patients were sum-
marized over longer time periods and were then published in
separate reports. The treatment modifications and the main
results of larger studies reporting results with ATRA and
chemotherapy are listed in Tables 3 and 4. The rate of high-
risk patients shows a broad range and is almost lower
compared to studies including the whole APL population
(Table 1). Furthermore, there is a considerable variability
regarding intensity and combination of the chemotherapy














Mandelli (2005) [31] 134 66 (60–75) – 14 ATRA + Ida 1–3 Yes
Sanz (2004) [32] 104 68 (60–83) 20 33 ATRA + Ida 3 Yes
Ades (2005) [33] 129 66 (62–70) – 0 ATRA + AD 1–2 Yes
Lataglia (2010) [34] 60 66 (60–73) 14 – ATRA + Ida 1 Yes
Ono (2011) [35] 46 63 (60–70) 20 0 ATRA + Ida + Ara-C 3 Yes
Lengfelder (2013) [23] 56 67 (60–83) 32 32 ATRA + TAD (±HAM) 1 Yes
ATRA all-trans retinoic acid, Ida idarubicin, ara-C cytosine arabinoside, AD ara-C daunorubicin, TAD 6-thioguanine ara-C daunorubicin, HAM
high-dose ara-C mitoxantrone
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regimens. Therefore, a comparison of the study results is
problematic. Nevertheless, some conclusions are possible.
In elderly patients treated in these studies, the CR rate
was lower (82 to 90 %) and the ED rate higher (11 to 18 %)
(Table 4) compared to results of younger study patients
mostly reaching CR rates between 90 and 95 % [6, 24].
This may, in part, be explained by the worse tolerance of
chemotherapy-related side effects by older patients. Other
factors with negative impact on the ED rate are high initial
WBC count and very advanced age. In the study of the
German AMLCG including 32 % elderly patients with
initial WBC count above 10,000/μl, the ED rate in patients
with WBC counts below and above 10,000/μl was 8 and
39 %, respectively (p=0.009) [23]. Notably, in patients with
high WBC counts aged between 60 and 69 years, the ED
rate was 25 %, and in patients 70 years or older, it was 67 %.
It is an important goal in APL treatment to avoid death in
CR, particularly due to toxicity of frontline therapy, as
relapsed patients have an excellent chance to be cured with
salvage regimens [40–42]. The rates of death in CR, which
may be in part related to the vulnerability against the che-
motherapy, were uniformly higher in elderly patients when
compared to younger age groups [23, 31–35]. According to
results of the updated French/European APL 93 study, the
rate of death in CR was 19 % in patients over 60 years as
compared to 6 % in patients aged 18 to 60 years (p=0.05)
[43]. The German AMLCG reported a rate of death in CR of
24 % at 10 years in patients over 60 years. In approximately
half of these patients, the chemotherapy-related toxicity had
influence on the fatal outcome [23]. In an amended Italian
ATRA and idarubicin (AIDA) protocol for elderly patients,
the second and third consolidation cycle of the original
protocol was omitted, and intermittent ATRA maintenance
was given to all patients. Compared to the original protocol,
the rate of death in CR was reduced from 13 to 8 % [31, 34].
In the Japanese study, in which a relatively dose-intensive
regimen was administered, 5 of 36 elderly patients (13 %)
died before or during consolidation therapy [35]. The Span-
ish PETHEMA reported 4 deaths among 86 elderly patients
(5 %) during consolidation therapy [32].
Long-term remission and probable cure was achieved in
more than 50 % of the elderly patients [23, 31–35]. The
rates of overall survival (OS), disease-free survival (DFS),
and the cumulative incidence of relapse (CIR) of studies are
shown in Table 4. The probability of relapse seems to be
influenced by the intensity of the chemotherapy and by the
risk profile of the patients. Detailed results of the amended
AIDA protocol with reduced chemotherapy showed a mod-
erate increase of the CIR of 27 % compared to 23 % of the
historical original protocol, but an improved OS of 76
versus 56 %, respectively [34]. The German AMLCG
reported a significantly inferior 7-year OS and CIR of 26
and 58 % in patients with initial WBC counts over
10,000/μl compared to 55 and 13 %, respectively, in pa-
tients with lower WBC counts. In 14 selected patients who
received treatment intensification with a second induction
cycle consisting of age-adapted high-dose ara-C and
mitoxantrone (HAM), the DFS was 83 % [23]. Very long-
term results of the updated ALP 93 study showed a 10-year
OS survival of 77 % of the whole study population com-
pared to 58 % of the elderly group (range of WBC counts,
900 to 1,900/μl) [43].
ATRA and chemotherapy-based treatment in patients
with advanced age over 70 years
There are only few reports on elderly APL patients of
advanced age over 70 years. In the report of the APL 93
study, results of 34 (6 %) patients over 70 years were
included. Even in these patients, a CR rate of 85 % was
achieved [33]. The German AMLCG registered 33 patients
over 70 years among 91 patients aged 60 years or older. Of
56 patients treated with 6-thioguanine, ara-C, and daunoru-
bicin (TAD) ± HAM, 18 patients (32 %) were older than
70 years. The CR rate was 89 % in the age group between
60 to 69 years compared to 67 % in patients 70 years or
older (p=0.06). The 7-year OS was 54 versus 25 %, respec-
tively (p=0.048), but DFS and CIR showed no difference
[23].
Table 4 Outcome in elderly APL patients with ATRA and chemotherapy
Author (year) [reference] Number of patients CR (%) ED (%) OS (%) EFS (%) DFS (%) CIR (%) Years
Mandelli (2003) [31] 134 86 12 56 – 59 – –
Sanz (2004) [32] 104 84 15 – – 79 9 6
Ades (2005) [33] 129 86 14 58 53 – 16 4
Lataglia (2011) [34] 60 90 10 69 – 65 27 5
Ono (2012 [35]) 46 89 11 63 – 65 15 10
Lengfelder (2013) [23] 56 82 18 45 40 48 24 7
CR complete remission, ED early death, OS overall survival, EFS event-free survival, DFS disease-free survival, CIR cumulative incidence of
relapse
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From 1999 to 2006, 297 patients aged over 70 years with
newly diagnosed AML were seen at a single Canadian
center. Among these were 13 patients (4 %) with APL. Their
median age was 78 years. Three patients (23 %) had high-
risk APL according to the Sanz score. The therapy consisted
of ATRA in combination with daunorubicin and ara-C. In
patients with impaired left ventricular function, daunorubi-
cin was replaced by amsacrine. The CR rate was 92 %, and
the 2-year OS and DFS were 76 and 59 %, respectively [44].
In an Italian multicenter experience, results of 34 patients
over 60 years were reported. The median age was 70 years.
Twenty-one percent had high risk according to the Sanz
score. Twenty-three patients (68 %) received treatment
according to the GIMEMA AIDA protocol, and 11 (32 %)
had a personalized approach because of bad performance
status or cardiomyopathy. In patients treated according to
the protocol, the CR rate was 74 %, and in the non-eligible
patients, it was 54 %. Ten of 11 patients with ED died from
cerebral hemorrhage. The median OS was 38 months [45].
In sporadic elderly patients up to 85 years not qualifying
for chemotherapy, ATRA without or combined with low-
dose chemotherapy was able to induce remission lasting
longer than 3 years. ATRA combined with hydroxyurea
for control of leukocytosis is therefore still an option for
patients with contraindications against chemotherapy or ar-
senic trioxide (ATO) [34, 46].
Treatment based on ATO or gemtuzumab ozogamicin
in frontline therapy or relapse
ATO is the most active single agent in treatment of APL.
The drug is considerably less toxic compared to approaches
with conventional chemotherapy. In particular, treatment-
related cytopenia is reduced and cardiotoxicity of
anthracyclines can be avoided [40]. The most frequently
administered ATO dose was 0.015 μg/kg/day, but lower
doses were reported to be effective as well [47]. The com-
bination with ATRAwas shown to increase the antileukemic
efficacy leading to a faster and more extensive reduction of
the leukemic clone compared to ATO alone [48]. In most
studies reporting results of ATO in frontline therapy, only
small numbers of elderly patients have been included.
Recently, a Chinese group presented the results of 33
elderly patients with newly diagnosed APL aged between
60 and 79 years (median age, 65 years) treated with ATO
monotherapy for induction of remission followed by post-
remission therapy with intermittent ATO over 4 years.
Eighty-five percent had low/intermediate and 15 % had high
risk according to the Sanz score. The rate of hematological
CR separated into low, intermediate, and high risk was 100,
86, and 80 %, respectively. Three patients died from ED due
to hemorrhage. Side effects (CTC grade 3/4), probably
related to ATO, were very low. OS, DFS, and cause-
specific survival (time from the first day of ATO therapy
to death attributed to APL disease or ATO treatment) were
69, 65, and 85 %, respectively [49]. Very recently, an 86-
year-old Chinese patient with newly diagnosed APL was
reported, who entered molecular remission after 60 days of
treatment with low-dose ATO (0.05 mg/kg/day) followed by
low-dose ATRA (15 mg/m2/day [50]).
In relapsed APL, a number of smaller studies with ATO
with or without ATRAwere reported. Many studies included
elderly patients but did not separately report age-related
results [42]. In the US pivotal multicenter study, which
included the highest number of patients reported so far,
8 of 40 patients were 60 years or older. Six (75 %) of the
older patients and 28 of 32 (88 %) younger patients
achieved CR. The 18-month OS of the older patients was
38 % compared to 73 % in patients aged from 18 to 59 years
[51]. The different outcome may be influenced by the sub-
sequent stem cell transplantation, which is usually restricted
to younger age [52]. According to a historical comparison of
French patients with relapsed APL, remission induction
with ATO was less toxic compared to conventional therapy
with ATRA and chemotherapy, and led to an improved
feasibility of transplantation and to a reduction of the
transplant-related mortality [40, 53]. Among nine patients
from Italy with molecular or hematologic relapse of APL,
three were older than 60 years. Eight patients had
low/intermediate and one patient had high risk according
to the Sanz score. All patients entered molecular remission
lasting from 10 months to over 50 months after ATO plus
ATRA [54].
Gemtuzumab ozogamicin (GO) is a humanized IgG4
anti-CD33 antibody conjugated with calicheamicin, a
stable derivative of a natural tumor antibiotic. The
unconjugated antibody is relatively untoxic and primar-
ily facilitates the uptake of the calicheamicin derivative
into CD33-positive cells. Intracellularly, calicheamicin
initiates single- or double-strand DNA breaks, similar
to anthracyclines, finally leading to apoptosis and cell
death. APL cells have a strong expression of CD33 and
are therefore suitable targets for anti-CD33 antibodies
including GO [55]. APL cells are further characterized by
a low expression of P-glycoprotein (P-170), probably respon-
sible for the particularly high sensitivity to anthracyclines [56,
57].
The clinical efficacy of GO in APL was shown in several
reports. In patients with first to fourth molecular relapse
after frontline therapy with the AIDA regimen, GO induced
remission in 9 (91 %) out of 11 patients tested after two
doses of 6 mg/m2 and in 13 (100 %) of 13 patients tested
after the third dose. The duration of remission was between
3 and over 31 months. GO was administered again in two
patients with molecular relapse, and both obtained a new
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molecular remission [58]. In newly diagnosed APL of youn-
ger patients, GO added to the effectiveness of ATRA and
could replace anthracyclines in the curative backbone of
treatment [59]. Some frail elderly patients were reported,
who entered molecular remission after ATRA and GO front-
line therapy, even with reduced dose of GO [34, 60, 61].
Conclusions
Elderly APL patients seem to be as sensitive to therapy as
younger patients and should be treated with the intention to
reach stabilization or cure, if possible. More than 50 % of
patients aged over 60 years included in trials can probably be
cured with conventional ATRA and anthracycline-based ther-
apy. Even very elderly or frail patients with contraindication
against the common standard therapy have a chance to reach
long-term remission or cure with less toxic approaches basing
on ATO with or without ATRA or, if applicable, combined
with reduced chemotherapy or GO, or even with ATRA alone.
The comparison of registry and study data indicates that
the study patients represent a positive selection. Older pa-
tients with high initial WBC counts and advanced age have
a very high risk and may therefore influence the results of
clinical trials negatively due to a higher rate of ED or death
in remission. Divergent study results in older age may
therefore not only be caused by differences of the treatment
regimens but also by the risk profile of the patients. Less
intensive chemotherapy has the advantage of a lower rate of
treatment-associated mortality and the disadvantage of a
higher rate of relapse. Intensive treatment regimens are
associated with high antileukemic efficacy but are restricted
to selected patients.
Hence, new less toxic approaches with broader applica-
bility are needed to improve the prognosis of the older APL
patients. The published data with ATO in elderly patients are
limited. A recent Italian–German study randomly compared
ATRA and ATO with ATRA and chemotherapy in frontline
therapy of low/intermediate-risk patients [62]. The superior
outcome of patients assigned to the ATO-plus-ATRA arm
and the lower toxicity of this therapy indicate that older
patients probably represent a particular target group for
ATO-based approaches. This should be investigated in larg-
er clinical trials.
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